{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:38:53Z","timestamp":1785839933681,"version":"3.56.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013227","name":"Ministry of Health and Welfare, Taiwan | Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW112-TDU-B-212-144004"],"award-info":[{"award-number":["MOHW112-TDU-B-212-144004"]}],"id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-111-105"],"award-info":[{"award-number":["DMR-111-105"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41433-024-03348-y","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T14:02:27Z","timestamp":1727532147000},"page":"3511-3518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The association between antiglaucomatous agents and Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-0900","authenticated-orcid":false,"given":"Chien-Chih","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-An","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-1263","authenticated-orcid":false,"given":"Chien-Hsiang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-8540","authenticated-orcid":false,"given":"Hui-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3045-0614","authenticated-orcid":false,"given":"I-Jong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuu-Shuh","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-245X","authenticated-orcid":false,"given":"Fuu-Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1542-6760","authenticated-orcid":false,"given":"Yih-Dih","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ju","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-han","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9099-3151","authenticated-orcid":false,"given":"Peng-Tai","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"3348_CR1","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"JD Steinmetz","year":"2021","unstructured":"Steinmetz JD, Bourne RRA, Briant PS, Flaxman SR, Taylor HRB, Jonas JB, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144\u2013e160.","journal-title":"Lancet Glob Health"},{"key":"3348_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2020.21899","volume":"325","author":"JD Stein","year":"2021","unstructured":"Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults\u2014screening, diagnosis, and management: a review. JAMA. 2021;325:164\u201374.","journal-title":"JAMA"},{"key":"3348_CR3","unstructured":"Dietze J, Blair K, Havens SJ Glaucoma. StatPearls. StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC.: Treasure Island (FL); 2023."},{"key":"3348_CR4","doi-asserted-by":"crossref","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dementia. 2020;16:391-460.","DOI":"10.1002\/alz.12068"},{"key":"3348_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15:455\u2013532.","journal-title":"Lancet Neurol"},{"key":"3348_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/cts.12755","volume":"13","author":"AV Morant","year":"2020","unstructured":"Morant AV, Vestergaard HT, Lassen AB, Navikas V. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer\u2019s Disease: Implications for Global Drug Development. Clin Transl Sci. 2020;13:652\u201364.","journal-title":"Clin Transl Sci"},{"key":"3348_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0039-1678581","volume":"39","author":"A Atri","year":"2019","unstructured":"Atri A. Current and future treatments in Alzheimer\u2019s disease. Semin Neurol. 2019;39:227\u201340.","journal-title":"Semin Neurol"},{"key":"3348_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jalz.2017.12.006","volume":"14","author":"J Jia","year":"2018","unstructured":"Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer\u2019s disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018;14:483\u201391.","journal-title":"Alzheimers Dement"},{"key":"3348_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S1474-4422(18)30053-X","volume":"17","author":"SJ van der Lee","year":"2018","unstructured":"van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, Amin N, et al. The effect of APOE and other common genetic variants on the onset of Alzheimer\u2019s disease and dementia: a community-based cohort study. Lancet Neurol. 2018;17:434\u201344.","journal-title":"Lancet Neurol"},{"key":"3348_CR10","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"3348_CR11","first-page":"313","volume":"8","author":"XX Zhang","year":"2021","unstructured":"Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of Alzheimer\u2019s disease modifiable risk factors and prevention. J Prev Alzheimers Dis. 2021;8:313\u201321.","journal-title":"J Prev Alzheimers Dis"},{"key":"3348_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnagi.2018.00083","volume":"10","author":"C Zhang","year":"2018","unstructured":"Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID exposure and risk of Alzheimer\u2019s disease: an updated meta-analysis from cohort studies. Front Aging Neurosci. 2018;10:83.","journal-title":"Front Aging Neurosci"},{"key":"3348_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401\u20137.","journal-title":"JAMA Intern Med"},{"key":"3348_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s12031-020-01478-y","volume":"70","author":"S Salarinasab","year":"2020","unstructured":"Salarinasab S, Salimi L, Alidadiani N, Shokrollahi E, Arzhanga P, Karbasforush S, et al. Interaction of opioid with insulin\/IGFs signaling in Alzheimer\u2019s disease. J Mol Neurosci. 2020;70:819\u201334.","journal-title":"J Mol Neurosci"},{"key":"3348_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/archinte.158.3.221","volume":"158","author":"WC Stewart","year":"1998","unstructured":"Stewart WC, Garrison PM. \u03b2-blocker\u2013induced complications and the patient with glaucoma: newer treatments to help reduce systemic adverse events. Arch Intern Med. 1998;158:221\u20136.","journal-title":"Arch Intern Med"},{"key":"3348_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/clc.4960190904","volume":"19","author":"WC Stewart","year":"1996","unstructured":"Stewart WC, Castelli WP. Systemic side effects of topical beta-adrenergic blockers. Clin Cardiol. 1996;19:691\u20137.","journal-title":"Clin Cardiol"},{"key":"3348_CR17","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/j.ophtha.2005.06.035","volume":"112","author":"S Al-Shahwan","year":"2005","unstructured":"Al-Shahwan S, Al-Torbak AA, Turkmani S, Al-Omran M, Al-Jadaan I, Edward DP. Side-effect profile of brimonidine tartrate in children. Ophthalmology. 2005;112:2143.","journal-title":"Ophthalmology"},{"key":"3348_CR18","first-page":"Doc25","volume":"10","author":"CP Azarcon","year":"2020","unstructured":"Azarcon CP, Santiago DE. Prolonged central nervous system and respiratory depression in preterm neonates after exposure to brimonidine tartrate and timolol maleate ophthalmic drops. GMS Ophthalmol Cases. 2020;10:Doc25.","journal-title":"GMS Ophthalmol Cases"},{"key":"3348_CR19","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/S0039-6257(03)00005-5","volume":"48","author":"W Tatton","year":"2003","unstructured":"Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer\u2019s disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol. 2003;48:S25\u201337.","journal-title":"Surv Ophthalmol"},{"key":"3348_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0893-133X(98)00093-1","volume":"20","author":"P Riekkinen Jr","year":"1999","unstructured":"Riekkinen P Jr, Riekkinen M. THA improves word priming and clonidine enhances fluency and working memory in Alzheimer\u2019s disease. Neuropsychopharmacology. 1999;20:357\u201364.","journal-title":"Neuropsychopharmacology"},{"key":"3348_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/brain\/awac076","volume":"146","author":"EE Beaman","year":"2023","unstructured":"Beaman EE, Bonde AN, Larsen SMU, Ozenne B, Lohela TJ, Nedergaard M, et al. Blood-brain barrier permeable \u03b2-blockers linked to lower risk of Alzheimer\u2019s disease in hypertension. Brain. 2023;146:1141\u201351.","journal-title":"Brain"},{"key":"3348_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/EB.S293765","volume":"13","author":"JW Chan","year":"2021","unstructured":"Chan JW, Chan NCY, Sadun AA. Glaucoma as Neurodegeneration in the Brain. Eye Brain. 2021;13:21\u20138.","journal-title":"Eye Brain"},{"key":"3348_CR23","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/s41433-020-0836-x","volume":"34","author":"S Sen","year":"2020","unstructured":"Sen S, Saxena R, Tripathi M, Vibha D, Dhiman R. Neurodegeneration in Alzheimer\u2019s disease and glaucoma: overlaps and missing links. Eye (Lond). 2020;34:1546\u201353.","journal-title":"Eye (Lond)"},{"key":"3348_CR24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2174\/1570159X16666171206144045","volume":"16","author":"R Mancino","year":"2018","unstructured":"Mancino R, Martucci A, Cesareo M, Giannini C, Corasaniti MT, Bagetta G, et al. Glaucoma and Alzheimer disease: one age-related neurodegenerative disease of the brain. Curr Neuropharmacol. 2018;16:971\u20137.","journal-title":"Curr Neuropharmacol"},{"key":"3348_CR25","doi-asserted-by":"publisher","first-page":"e108938","DOI":"10.1371\/journal.pone.0108938","volume":"9","author":"IC Lin","year":"2014","unstructured":"Lin IC, Wang YH, Wang TJ, Wang IJ, Shen YD, Chi NF, et al. Glaucoma, Alzheimer\u2019s disease, and Parkinson\u2019s disease: an 8-year population-based follow-up study. PLoS One. 2014;9:e108938.","journal-title":"PLoS One"},{"key":"3348_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29557-6","volume":"8","author":"JY Moon","year":"2018","unstructured":"Moon JY, Kim HJ, Park YH, Park TK, Park EC, Kim CY, et al. Association between open-angle glaucoma and the risks of Alzheimer\u2019s and Parkinson\u2019s diseases in South Korea: a 10-year nationwide cohort study. Sci Rep. 2018;8:11161.","journal-title":"Sci Rep."},{"key":"3348_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/aos.14114","volume":"97","author":"XH Xu","year":"2019","unstructured":"Xu XH, Zou JY, Geng W, Wang AY. Association between glaucoma and the risk of Alzheimer\u2019s disease: a systematic review of observational studies. Acta Ophthalmol. 2019;97:665\u201371.","journal-title":"Acta Ophthalmol"},{"key":"3348_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.688551","volume":"8","author":"W Zhao","year":"2021","unstructured":"Zhao W, Lv X, Wu G, Zhou X, Tian H, Qu X, et al. Glaucoma is not associated with Alzheimer\u2019s disease or dementia: a meta-analysis of cohort studies. Front Med (Lausanne). 2021;8:688551.","journal-title":"Front Med (Lausanne)"},{"key":"3348_CR29","unstructured":"National Health Insurance Research Database, Taiwan. Available at: http:\/\/nhird.nhri.org.tw\/en\/index.htm. Accessed August 28, 2023."},{"key":"3348_CR30","unstructured":"Unversal Health Coverage in Taiwan. February 10, 2023. Available at: https:\/\/eng.nhi.gov.tw\/en\/cp-5-96705-57-2.html. Accessed August 28, 2023."},{"key":"3348_CR31","doi-asserted-by":"crossref","unstructured":"Zhang F, Gannon M, Chen Y, Yan S, Zhang S, Feng W et al. \u03b2-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3\u03b2\/tau cascade. Sci Transl Med. 2020;12:eaay6931.","DOI":"10.1126\/scitranslmed.aay6931"},{"key":"3348_CR32","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.tips.2022.09.007","volume":"43","author":"N Persson","year":"2022","unstructured":"Persson N, Uusalo P, Nedergaard M, Lohela TJ, Lilius TO. Could dexmedetomidine be repurposed as a glymphatic enhancer? Trends Pharm Sci. 2022;43:1030\u201340.","journal-title":"Trends Pharm Sci"},{"key":"3348_CR33","unstructured":"Alpha2-adrenoceptors: Structure and ligand binding properties at the molecular level2011."},{"key":"3348_CR34","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1017\/S1461145713000631","volume":"16","author":"M Dobarro","year":"2013","unstructured":"Dobarro M, Gerenu G, Ram\u00edrez MJ. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer\u2019s transgenic mice. Int J Neuropsychopharmacol. 2013;16:2245\u201357.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3348_CR35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/JGP.0b013e318181276a","volume":"16","author":"PB Rosenberg","year":"2008","unstructured":"Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry. 2008;16:883\u201392.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3348_CR36","doi-asserted-by":"publisher","unstructured":"Sherpa, AD, Aoki C, Hrabetova S. Noradrenaline drives structural changes in astrocytes and brain extracellular space. In: Vardjan N, Zorec R, editors. Noradrenergic Signaling and Astroglia. Academic Press; 2016. p. 241\u2013255. https:\/\/doi.org\/10.1016\/B978-0-12-805088-0.00012-8.","DOI":"10.1016\/B978-0-12-805088-0.00012-8"},{"key":"3348_CR37","doi-asserted-by":"crossref","unstructured":"Han F, Chen J, Belkin-Rosen A, Gu Y, Luo L, Buxton OM et al. The coupling of global brain activity and cerebrospinal fluid inflow is correlated with Alzheimer\u2019s disease related pathology. bioRxiv 2020:2020.2006.2004.134726.","DOI":"10.1101\/2020.06.04.134726"},{"key":"3348_CR38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/brain\/awaa443","volume":"144","author":"PK Eide","year":"2021","unstructured":"Eide PK, Vinje V, Pripp AH, Mardal KA, Ringstad G. Sleep deprivation impairs molecular clearance from the human brain. Brain. 2021;144:863\u201374.","journal-title":"Brain"},{"key":"3348_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1001\/jamaneurol.2016.4370","volume":"74","author":"DM Zeppenfeld","year":"2017","unstructured":"Zeppenfeld DM, Simon M, Haswell JD, D\u2019Abreo D, Murchison C, Quinn JF, et al. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 2017;74:91\u201399.","journal-title":"JAMA Neurol"},{"key":"3348_CR40","doi-asserted-by":"publisher","first-page":"e3000623","DOI":"10.1371\/journal.pbio.3000623","volume":"18","author":"SM Ulv Larsen","year":"2020","unstructured":"Ulv Larsen SM, Landolt HP, Berger W, Nedergaard M, Knudsen GM, Holst SC. Haplotype of the astrocytic water channel AQP4 is associated with slow wave energy regulation in human NREM sleep. PLoS Biol. 2020;18:e3000623.","journal-title":"PLoS Biol"},{"key":"3348_CR41","unstructured":"Gabel TL Chapter 20 - Sleep Pharmacology. In: Barkoukis TJ, Avidan AY (eds). Review of Sleep Medicine (Second Edition). Butterworth-Heinemann: Philadelphia; 2007. pp 385-99."},{"key":"3348_CR42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/sj.bjp.0703369","volume":"130","author":"G Chidlow","year":"2000","unstructured":"Chidlow G, Melena J, Osborne NN. Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharm. 2000;130:759\u201366.","journal-title":"Br J Pharm"},{"key":"3348_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/bjaceaccp\/mkr018","volume":"11","author":"BK Lawther","year":"2011","unstructured":"Lawther BK, Kumar S, Krovvidi H. Blood\u2013brain barrier. Continuing Educ Anaesth Crit Care Pain. 2011;11:128\u201332.","journal-title":"Continuing Educ Anaesth Crit Care Pain"},{"key":"3348_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00417-002-0462-2","volume":"240","author":"JM Korte","year":"2002","unstructured":"Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002;240:430\u20135.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3348_CR45","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/ijms22052360","volume":"22","author":"L Wang","year":"2021","unstructured":"Wang L, Mao X. Role of retinal amyloid-\u03b2 in neurodegenerative diseases: overlapping mechanisms and emerging clinical applications. Int J Mol Sci. 2021;22:2360.","journal-title":"Int J Mol Sci"},{"key":"3348_CR46","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00401-016-1613-6","volume":"132","author":"NJ Hart","year":"2016","unstructured":"Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer\u2019s: exploring disease in the retina. Acta Neuropathologica. 2016;132:767\u201387.","journal-title":"Acta Neuropathologica"},{"key":"3348_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:535\u201362.","journal-title":"Alzheimer\u2019s Dement"},{"key":"3348_CR48","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-023-02548-2","volume":"145","author":"Y Koronyo","year":"2023","unstructured":"Koronyo Y, Rentsendorj A, Mirzaei N, Regis GC, Sheyn J, Shi H, et al. Retinal pathological features and proteome signatures of Alzheimer\u2019s disease. Acta Neuropathologica. 2023;145:409\u201338.","journal-title":"Acta Neuropathologica"},{"key":"3348_CR49","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/0006-8993(89)90653-7","volume":"501","author":"JC Blanks","year":"1989","unstructured":"Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer\u2019s disease. Brain Res. 1989;501:364\u201372.","journal-title":"Brain Res"},{"key":"3348_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/0197-4580(96)00009-7","volume":"17","author":"JC Blanks","year":"1996","unstructured":"Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal pathology in Alzheimer\u2019s disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17:385\u201395.","journal-title":"Neurobiol Aging"},{"key":"3348_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.108974","volume":"221","author":"JA Moncaster","year":"2022","unstructured":"Moncaster JA, Moir RD, Burton MA, Chadwick O, Minaeva O, Alvarez VE, et al. Alzheimer\u2019s disease amyloid-\u03b2 pathology in the lens of the eye. Exp Eye Res. 2022;221:108974.","journal-title":"Exp Eye Res"},{"key":"3348_CR52","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(03)12981-9","volume":"361","author":"LE Goldstein","year":"2003","unstructured":"Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer\u2019s disease. Lancet. 2003;361:1258\u201365.","journal-title":"Lancet"},{"key":"3348_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exer.2007.10.021","volume":"87","author":"ML Chalasani","year":"2008","unstructured":"Chalasani ML, Balasubramanian D, Swarup G. Focus on molecules: optineurin. Exp Eye Res. 2008;87:1\u20132.","journal-title":"Exp Eye Res"},{"key":"3348_CR54","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1167\/iovs.04-1133","volume":"46","author":"T Aung","year":"2005","unstructured":"Aung T, Rezaie T, Okada K, Viswanathan AC, Child AH, Brice G, et al. Clinical features and course of patients with glaucoma with the E50K mutation in the optineurin gene. Investig Ophthalmol Vis Sci. 2005;46:2816\u201322.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3348_CR55","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1066901","volume":"295","author":"T Rezaie","year":"2002","unstructured":"Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science. 2002;295:1077\u20139.","journal-title":"Science"},{"key":"3348_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02327-4","volume":"18","author":"L-L Cao","year":"2021","unstructured":"Cao L-L, Guan P-P, Zhang S-Q, Yang Y, Huang X-S, Wang P. Downregulating expression of OPTN elevates neuroinflammation via AIM2 inflammasome- and RIPK1-activating mechanisms in APP\/PS1 transgenic mice. J Neuroinflammation. 2021;18:281.","journal-title":"J Neuroinflammation"},{"key":"3348_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/jnc.13217","volume":"136","author":"LC Freeman","year":"2016","unstructured":"Freeman LC, Ting JP-Y. The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem. 2016;136:29\u201338.","journal-title":"J Neurochem"},{"key":"3348_CR58","doi-asserted-by":"publisher","first-page":"E8788","DOI":"10.1073\/pnas.1714175114","volume":"114","author":"D Ofengeim","year":"2017","unstructured":"Ofengeim D, Mazzitelli S, Ito Y, DeWitt JP, Mifflin L, Zou C, et al. RIPK1 mediates a disease-associated microglial response in Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2017;114:E8788\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3348_CR59","doi-asserted-by":"publisher","first-page":"e022987","DOI":"10.1136\/bmjopen-2018-022987","volume":"8","author":"Y-Y Chen","year":"2018","unstructured":"Chen Y-Y, Lai Y-J, Yen Y-F, Shen Y-C, Wang C-Y, Liang C-Y, et al. Association between normal tension glaucoma and the risk of Alzheimer\u2019s disease: a nationwide population-based cohort study in Taiwan. BMJ Open. 2018;8:e022987.","journal-title":"BMJ Open"},{"key":"3348_CR60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1755-3768.2011.02125.x","volume":"90","author":"D Bach-Holm","year":"2012","unstructured":"Bach-Holm D, Kessing SV, Mogensen U, Forman JL, Andersen PK, Kessing LV. Normal tension glaucoma and Alzheimer disease: comorbidity? Acta Ophthalmol. 2012;90:683\u20135.","journal-title":"Acta Ophthalmol"},{"key":"3348_CR61","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamaneurol.2022.0092","volume":"79","author":"J Deal","year":"2022","unstructured":"Deal J, Rojas JC. Visual impairment as a modifiable risk factor in dementia prevention and management. JAMA Neurol. 2022;79:542\u20133.","journal-title":"JAMA Neurol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03348-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03348-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03348-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T17:02:55Z","timestamp":1733418175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03348-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":61,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3348"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03348-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}